Vigil Neuroscience, Inc. (NASDAQ:VIGL) Shares Bought by Blair William & Co. IL

Key Points

• Blair William & Co. IL increased its holdings in Vigil Neuroscience by 219.1% during the 1st quarter, owning over 1 million shares valued at approximately $1.84 million.
• Several institutional investors, including Cubist Systematic Strategies LLC and Barclays PLC, also boosted their stakes in Vigil Neuroscience during the fourth quarter, indicating growing confidence in the stock.
• Despite recent downgrades from multiple analysts, Vigil Neuroscience's consensus rating remains a "Hold", with a target price of $10.80.

Blair William & Co. IL grew its holdings in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 219.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,033,577 shares of the company's stock after buying an additional 709,677 shares during the quarter. Blair William & Co. IL owned 2.10% of Vigil Neuroscience worth $1,840,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Cubist Systematic Strategies LLC raised its position in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Vigil Neuroscience during the 4th quarter valued at approximately $83,000. Barclays PLC raised its position in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after acquiring an additional 19,436 shares in the last quarter. Northern Trust Corp raised its position in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after acquiring an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Vigil Neuroscience by 243.8% during the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock valued at $117,000 after acquiring an additional 49,000 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VIGL has been the topic of several research reports. William Blair lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Stifel Nicolaus lowered Vigil Neuroscience from a "buy" rating to a "hold" rating and dropped their target price for the stock from $11.00 to $8.00 in a research report on Wednesday, May 28th. Guggenheim set a $8.00 target price on Vigil Neuroscience and gave the stock a "neutral" rating in a research report on Thursday, May 22nd. Citizens Jmp lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Vigil Neuroscience currently has an average rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Price Performance

Shares of VIGL remained flat at $8.05 during trading hours on Wednesday. The firm has a market cap of $383.90 million, a price-to-earnings ratio of -3.93 and a beta of 3.33. Vigil Neuroscience, Inc. has a twelve month low of $1.31 and a twelve month high of $8.10. The company has a 50-day simple moving average of $7.99 and a two-hundred day simple moving average of $4.56.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.